Market Cap 11.13M
Revenue (ttm) 0.00
Net Income (ttm) -23.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.11
Volume 2,565,865
Avg Vol 26,074,160
Day's Range N/A - N/A
Shares Out 33.74M
Stochastic %K 0%
Beta 1.17
Analysts Strong Sell
Price Target $2.50

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for trea...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 417 4364
Address:
9605 Medical Center Drive, Suite 270, Rockville, United States
Oreos62
Oreos62 May. 15 at 7:55 PM
$TOVX what a disaster
0 · Reply
StockBoySam
StockBoySam May. 15 at 7:50 PM
$TOVX Is Andy T back as another insider shill profile? Let’s prevent further dilution. Vote No as i am doing.
0 · Reply
StockBoySam
StockBoySam May. 15 at 7:46 PM
$TOVX The only thing this company is good at is stock manipulation and hurting retail investors. Vote NO.
0 · Reply
Congratulations
Congratulations May. 15 at 7:17 PM
$TOVX they’ll run it up
1 · Reply
exwallstcfo
exwallstcfo May. 15 at 3:28 PM
$TOVX Management at it again .... this time trying to get it under 30c as though this will change the mind of shareholders ..... VOTE NO !!! explain yourself what raising 8.7 m will do . ..... DO YOUR JOB AND SELL !!!! ..... Im tired off supporting you and your wife ... the spot light needs to come down on you for your BS ..... I yearn the day for when the law comes for you
0 · Reply
Congratulations
Congratulations May. 15 at 3:22 PM
0 · Reply
Tradelyfe
Tradelyfe May. 15 at 3:16 PM
$TOVX what a dump haha Tutes fleeing
0 · Reply
Lovelife68
Lovelife68 May. 15 at 3:14 PM
$TOVX 8 million dollars won’t fund phase 3 only Shallcross salary and golden parachute
0 · Reply
Thess5
Thess5 May. 15 at 3:11 PM
$TOVX Down she goes! When RS? When more shares? .10 incoming!
0 · Reply
WallStreetLiving
WallStreetLiving May. 15 at 12:53 PM
$TOVX clinical trials have a 3-12% chance of ever making it to FDA approval. Dilution are companies trying over and over for that small chance of success. This company $TOVX owns VCN-01, validated in 144 patients across multiple clinical trials including the Phase 2b VIRAGE study, which showed 31.1% 18-month overall survival versus 8.52% for chemotherapy alone, with both the FDA and EMA independently aligning on the Phase 3 design. The science was developed over 30 years by Dr. Ramon Alemany one of the world's leading virus researchers with 225 published papers and 9,458 citations. Which means the inventor is still in the building advancing his life's work. The company holds Rare Pediatric Drug Designation for VCN-01 in retinoblastoma with a potential Priority Review Voucher worth $100-150M if approved before September 2029 — an asset worth more a June 5 warrant vote that if successful raises $8.7M and substantially resolves the going concern pressure.
0 · Reply
Latest News on TOVX
Theriva Biologics upgraded to Buy from Hold at Maxim

2026-03-31T11:54:39.000Z - 6 weeks ago

Theriva Biologics upgraded to Buy from Hold at Maxim


Theriva Biologics sees cash runway into 1Q27

2026-03-12T12:05:50.000Z - 2 months ago

Theriva Biologics sees cash runway into 1Q27


Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

2026-02-18T13:16:44.000Z - 3 months ago

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics


Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year

2025-11-12T13:16:18.000Z - 6 months ago

Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year


Theriva Biologics Provides Response to Unusual Market Action

Oct 24, 2025, 2:31 PM EDT - 7 months ago

Theriva Biologics Provides Response to Unusual Market Action


Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year

2025-08-11T12:12:44.000Z - 9 months ago

Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year


Theriva Biologics sees cash runway into 1Q26

2025-08-11T12:12:22.000Z - 9 months ago

Theriva Biologics sees cash runway into 1Q26


Theriva Biologics sees cash runway into 1Q26

2025-05-14T12:52:08.000Z - 1 year ago

Theriva Biologics sees cash runway into 1Q26


Theriva Biologics downgraded to Hold from Buy at Maxim

2025-05-08T12:43:45.000Z - 1 year ago

Theriva Biologics downgraded to Hold from Buy at Maxim


Theriva Biologics Announces Reverse Stock Split

Aug 16, 2024, 4:05 PM EDT - 1 year ago

Theriva Biologics Announces Reverse Stock Split


Theriva Biologics Earnings Call Transcript: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Earnings Call Transcript: Q4 2023


Theriva Biologics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Theriva Biologics Earnings Call Transcript: Q3 2023


Theriva Biologics Earnings Call Transcript: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q2 2023


Theriva Biologics Earnings Call Transcript: Q1 2023

May 11, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q1 2023


Theriva Biologics Earnings Call Transcript: Q4 2022

Mar 30, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q4 2022


Oreos62
Oreos62 May. 15 at 7:55 PM
$TOVX what a disaster
0 · Reply
StockBoySam
StockBoySam May. 15 at 7:50 PM
$TOVX Is Andy T back as another insider shill profile? Let’s prevent further dilution. Vote No as i am doing.
0 · Reply
StockBoySam
StockBoySam May. 15 at 7:46 PM
$TOVX The only thing this company is good at is stock manipulation and hurting retail investors. Vote NO.
0 · Reply
Congratulations
Congratulations May. 15 at 7:17 PM
$TOVX they’ll run it up
1 · Reply
exwallstcfo
exwallstcfo May. 15 at 3:28 PM
$TOVX Management at it again .... this time trying to get it under 30c as though this will change the mind of shareholders ..... VOTE NO !!! explain yourself what raising 8.7 m will do . ..... DO YOUR JOB AND SELL !!!! ..... Im tired off supporting you and your wife ... the spot light needs to come down on you for your BS ..... I yearn the day for when the law comes for you
0 · Reply
Congratulations
Congratulations May. 15 at 3:22 PM
0 · Reply
Tradelyfe
Tradelyfe May. 15 at 3:16 PM
$TOVX what a dump haha Tutes fleeing
0 · Reply
Lovelife68
Lovelife68 May. 15 at 3:14 PM
$TOVX 8 million dollars won’t fund phase 3 only Shallcross salary and golden parachute
0 · Reply
Thess5
Thess5 May. 15 at 3:11 PM
$TOVX Down she goes! When RS? When more shares? .10 incoming!
0 · Reply
WallStreetLiving
WallStreetLiving May. 15 at 12:53 PM
$TOVX clinical trials have a 3-12% chance of ever making it to FDA approval. Dilution are companies trying over and over for that small chance of success. This company $TOVX owns VCN-01, validated in 144 patients across multiple clinical trials including the Phase 2b VIRAGE study, which showed 31.1% 18-month overall survival versus 8.52% for chemotherapy alone, with both the FDA and EMA independently aligning on the Phase 3 design. The science was developed over 30 years by Dr. Ramon Alemany one of the world's leading virus researchers with 225 published papers and 9,458 citations. Which means the inventor is still in the building advancing his life's work. The company holds Rare Pediatric Drug Designation for VCN-01 in retinoblastoma with a potential Priority Review Voucher worth $100-150M if approved before September 2029 — an asset worth more a June 5 warrant vote that if successful raises $8.7M and substantially resolves the going concern pressure.
0 · Reply
CeaseNDesist
CeaseNDesist May. 15 at 12:36 PM
$TOVX more dillution coming
0 · Reply
CeaseNDesist
CeaseNDesist May. 15 at 12:35 PM
$TOVX legalized theft
0 · Reply
Lovelife68
Lovelife68 May. 14 at 7:41 PM
$TOVX SEC turns a blind eye to the most blatant and obvious manipulation holding this stock down sad.
0 · Reply
ibioRz
ibioRz May. 14 at 6:12 PM
$TOVX when to fly?
0 · Reply
dogood
dogood May. 14 at 4:50 PM
$EOSE all Going to go wild $EOSE $AGAE $TOVX $WLDS $GNPX watch
0 · Reply
WallStreetLiving
WallStreetLiving May. 14 at 2:53 PM
$TOVX is a real company doing real science. True investors are not trying to make a quick buck. Phase 2b clinical data showed improved overall survival and progression-free survival in first-line metastatic pancreatic cancer when VCN-01 is added to standard chemotherapy, along with full FDA and EMA alignment on the Phase 3 trial design has huge real world impact. Now they need money to fund Phase 3. Partnership is best result and stock would skyrocket especially with the extremely attractive short squeeze setup with an 18.85% short float and one of the highest borrow rates we’ve seen (182.89%), which could drive sharp upside if positive news. But voting no would crush the upcoming trials. A successful vote is generally positive for the company’s survival and the stock’s near-term stability. A failure would increase risk significantly.
2 · Reply
WallStreetLiving
WallStreetLiving May. 14 at 1:37 PM
$TOVX Voting no is a crazy position and genuinely bad advice for anyone who believes in the VCN-01 science. If warrants are approved — $8.7M enters the treasury. Going concern pressure substantially diminishes. Cash runway extends into 2028. Partnership negotiations proceed from a position of stability not desperation. If warrants are rejected — company has roughly 3 quarters of runway left after Grifols payment. They're forced to raise capital on whatever terms the market offers which will be worse than $0.54 per share if the stock is at $0.33. The science doesn't change but the survival clock accelerates dramatically. Voting no to "force them to drive the price up" is gambling with the company's survival based on a theory that has no direct evidence supporting it.
1 · Reply
Lovelife68
Lovelife68 May. 14 at 1:32 PM
$TOVX Management needs investigated they had stock at 3.00 and stock got shorted and most likely the warrants were used to cover their shorts. This is blatant corruption..
0 · Reply
ka1954
ka1954 May. 14 at 11:06 AM
$TOVX while u r at it, why not say run like WOK from .19 to 10 ? LOL
0 · Reply
dogood
dogood May. 14 at 3:18 AM
$TOVX I wish she runs like $QUCY to $2 with solid news
0 · Reply
Dunqito
Dunqito May. 13 at 10:41 PM
$TOVX We are potentially in a Mexican Standoff unless the existing warrant holders can vote in their new shares. They might have been accumulating back the shares they may have sold to drive the price down to $0.17. There are roughly 46 million shares. We can suspect that they may still have the 7.3M they bought in October. They are described as being at least two existing institutional shareholders. So they had to have significant shares prior to October 15th, 2025. Apparently that wasn't enough though to vote in the shares as here we are voting again. But I am guessing they accumulated enough to get the vote. After the vote is approved, then will probably come the news of some magnitude, in order to sell the warrant shares that presently don't exist. Kind of a mess. But regardless: vote no. If they don't have the shares to sway the election that might force them to drive the price up. It's a mess.
2 · Reply
Dunqito
Dunqito May. 13 at 10:19 PM
$TOVX FROM SEC FILING October 16, 2025 "...a warrant inducement agreement with existing institutional investors (WHO ?) ... of warrants to purchase up to 7,360,460 of common stock at a reduced exercise price of $0.54 per share for cash of $4.0 M. (?WARRANTS AT $0.54 when the stock is $0.30?) In consideration of purchasing the Existing Warrants, the investors will receive, in a private placement, new unregistered warrants to purchase up to an aggregate of 14,720,920 of common stock shares (“New Warrants”) The New Warrants will have an exercise price of $0.54 per share & will be initially exercisable on the date that stockholder approval ... is obtained." They did not get the quorum/votes to issue the shares for warrants that have already been sold. The price is still below the exercise price by roughly 1/2. Also there was a price & volume surge at the time of this SEC PR. I am guessing the warrant holders are accumulating. If so they will vote in their warrants @ 0.54 Fine by me
0 · Reply